The Nala CDS Module-PGx Core and PGx Core qPCR kit are used together as a plug-and-play solution for labs using qPCR machines. Credit: Nalagenetics.

Biotechnology firm Nalagenetics has obtained CE Mark for its pharmacogenomics software, Nala Clinical Decision Support (CDS) Module-PGx Core.

The CE Mark will allow the company to market its CDS software in Europe and obtain regulatory approval in Southeast Asia, where it intends to increase its market share.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Nalagenetics stated that Nala CDS Module-PGx Core is a companion software to its Nala PGx Core qPCR kit, which genotypes top pharmacogenes to assist providers in running pre-emptive pharmacogenomics programmes economically.

For labs using qPCR machines, the Nala CDS Module-PGx Core and PGx Core qPCR kit can be used together as a plug-and-play solution.

The research-use-only kit reads 20 variants in four known pharmacogenes, including CYP2D6, CYP2C9, CYP2C19 and SLCO1B1, while the software can create up to 170 drug-gene reports.

See Also:

Nalagenetics noted that the kit is currently being validated with its partners in the UK and Malaysia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nalagenetics CEO Levana Sani said: “We are very excited about this milestone to build credibility in the European and home market in South East Asia.

“With pharmacogenomics testing becoming more and more ubiquitous around the world, it requires standardised and robust tools to support the rapid increase of adoption.”

qPCR is the base of clinical genomics. It has become widely available recently due to Covid-19 testing requirements.

The kit is positioned to assist the democratisation of personalised medication due to newly added genotyping capacity across the world, as well as the proven benefit of pharmacogenomics for mass screening of populations.

In collaboration with sequencing partners, Nala CDS is expanding into new applications beyond pharmacogenomics.